medi5884
mAbexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 17, 2017 (NCT03001297)
Timeline
Indications
Mechanism of action
- Endothelial lipaseINHIBITOR
LIPG inhibitor
Chemistry & pharmacology
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Also known as
- medi5884
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03351738 | Phase 2 | Dec 13, 2017 | Jacksonville Center for Clinical Research, MedImmune |
| NCT03001297 | Phase 1 | Jan 17, 2017 | MedImmune |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| MedImmune | For profit | 2 | 2 | 2 | 2017 |
| Jacksonville Center for Clinical Research | For profit | 1 | 0 | 1 | 2017 |
2 organizations
Page 1 / 1